Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer

PurposeThe clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine plus cisplatin were investigated.Materials and MethodsA total of 52 BTC patients treated with palliative gemcitabine plus cisplatin wer...

Full description

Saved in:
Bibliographic Details
Published inCancer research and treatment Vol. 53; no. 1; pp. 162 - 171
Main Authors Kim, Hyung-Don, Kim, Jwa Hoon, Ryu, Yeon-Mi, Kim, Danbee, Lee, Sunmin, Shin, Jaehoon, Hong, Seung-Mo, Kim, Ki-Hun, Jung, Dong‐Hwan, Song, Gi‐Won, Hwang, Dae Wook, Lee, Jae Hoon, Song, Ki Byung, Ryoo, Baek-Yeol, Jeong, Jae Ho, Kim, Kyu-pyo, Kim, Sang-Yeob, Yoo, Changhoon
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Cancer Association 01.01.2021
대한암학회
Subjects
Online AccessGet full text
ISSN1598-2998
2005-9256
2005-9256
DOI10.4143/crt.2020.704

Cover

Abstract PurposeThe clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine plus cisplatin were investigated.Materials and MethodsA total of 52 BTC patients treated with palliative gemcitabine plus cisplatin were included. Multiplexed immunohistochemistry was performed on tumor tissues, and immune infiltrates were separately analyzed for the stroma, tumor margin, and tumor core.ResultsThe density of CD8+ T cells, FoxP3- CD4+ helper T cells, and FoxP3+ CD4+ regulatory T cells was significantly higher in the tumor margin than in the stroma and tumor core. The density of LAG3- or TIM3-expressing CD8+ T cell and FoxP3- CD4+ helper T cell infiltrates was also higher in the tumor margin. In extrahepatic cholangiocarcinoma, there was a higher density of T cell subsets in the tumor core and regulatory T cells in all regions. A high density of FoxP3- CD4+ helper T cells in the tumor margin showed a trend toward better progression-free survival (PFS) (p=0.092) and significantly better overall survival (OS) (p=0.012). In multivariate analyses, a high density of FoxP3- CD4+ helper T cells in the tumor margin was independently associated with favorable PFS and OS. ConclusionThe tumor margin is the major site for the active infiltration of T cell subsets with higher levels of LAG3 and TIM3 expression in BTC. The density of tumor margin-infiltrating FoxP3- CD4+ helper T cells may be associated with clinical outcomes in BTC patients treated with gemcitabine plus cisplatin.
AbstractList The clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine plus cisplatin were investigated.PURPOSEThe clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine plus cisplatin were investigated.A total of 52 BTC patients treated with palliative gemcitabine plus cisplatin were included. Multiplexed immunohistochemistry was performed on tumor tissues, and immune infiltrates were separately analyzed for the stroma, tumor margin, and tumor core.MATERIALS AND METHODSA total of 52 BTC patients treated with palliative gemcitabine plus cisplatin were included. Multiplexed immunohistochemistry was performed on tumor tissues, and immune infiltrates were separately analyzed for the stroma, tumor margin, and tumor core.The density of CD8+ T cells, FoxP3- CD4+ helper T cells, and FoxP3+ CD4+ regulatory T cells was significantly higher in the tumor margin than in the stroma and tumor core. The density of LAG3- or TIM3-expressing CD8+ T cell and FoxP3- CD4+ helper T cell infiltrates was also higher in the tumor margin. In extrahepatic cholangiocarcinoma, there was a higher density of T cell subsets in the tumor core and regulatory T cells in all regions. A high density of FoxP3- CD4+ helper T cells in the tumor margin showed a trend toward better progression-free survival (PFS) (p=0.092) and significantly better overall survival (OS) (p=0.012). In multivariate analyses, a high density of FoxP3- CD4+ helper T cells in the tumor margin was independently associated with favorable PFS and OS.RESULTSThe density of CD8+ T cells, FoxP3- CD4+ helper T cells, and FoxP3+ CD4+ regulatory T cells was significantly higher in the tumor margin than in the stroma and tumor core. The density of LAG3- or TIM3-expressing CD8+ T cell and FoxP3- CD4+ helper T cell infiltrates was also higher in the tumor margin. In extrahepatic cholangiocarcinoma, there was a higher density of T cell subsets in the tumor core and regulatory T cells in all regions. A high density of FoxP3- CD4+ helper T cells in the tumor margin showed a trend toward better progression-free survival (PFS) (p=0.092) and significantly better overall survival (OS) (p=0.012). In multivariate analyses, a high density of FoxP3- CD4+ helper T cells in the tumor margin was independently associated with favorable PFS and OS.The tumor margin is the major site for the active infiltration of T cell subsets with higher levels of LAG3 and TIM3 expression in BTC. The density of tumor margin-infiltrating FoxP3- CD4+ helper T cells may be associated with clinical outcomes in BTC patients treated with gemcitabine plus cisplatin.CONCLUSIONThe tumor margin is the major site for the active infiltration of T cell subsets with higher levels of LAG3 and TIM3 expression in BTC. The density of tumor margin-infiltrating FoxP3- CD4+ helper T cells may be associated with clinical outcomes in BTC patients treated with gemcitabine plus cisplatin.
The clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine plus cisplatin were investigated. A total of 52 BTC patients treated with palliative gemcitabine plus cisplatin were included. Multiplexed immunohistochemistry was performed on tumor tissues, and immune infiltrates were separately analyzed for the stroma, tumor margin, and tumor core. The density of CD8+ T cells, FoxP3- CD4+ helper T cells, and FoxP3+ CD4+ regulatory T cells was significantly higher in the tumor margin than in the stroma and tumor core. The density of LAG3- or TIM3-expressing CD8+ T cell and FoxP3- CD4+ helper T cell infiltrates was also higher in the tumor margin. In extrahepatic cholangiocarcinoma, there was a higher density of T cell subsets in the tumor core and regulatory T cells in all regions. A high density of FoxP3- CD4+ helper T cells in the tumor margin showed a trend toward better progression-free survival (PFS) (p=0.092) and significantly better overall survival (OS) (p=0.012). In multivariate analyses, a high density of FoxP3- CD4+ helper T cells in the tumor margin was independently associated with favorable PFS and OS. The tumor margin is the major site for the active infiltration of T cell subsets with higher levels of LAG3 and TIM3 expression in BTC. The density of tumor margin-infiltrating FoxP3- CD4+ helper T cells may be associated with clinical outcomes in BTC patients treated with gemcitabine plus cisplatin.
PurposeThe clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine plus cisplatin were investigated.Materials and MethodsA total of 52 BTC patients treated with palliative gemcitabine plus cisplatin were included. Multiplexed immunohistochemistry was performed on tumor tissues, and immune infiltrates were separately analyzed for the stroma, tumor margin, and tumor core.ResultsThe density of CD8+ T cells, FoxP3- CD4+ helper T cells, and FoxP3+ CD4+ regulatory T cells was significantly higher in the tumor margin than in the stroma and tumor core. The density of LAG3- or TIM3-expressing CD8+ T cell and FoxP3- CD4+ helper T cell infiltrates was also higher in the tumor margin. In extrahepatic cholangiocarcinoma, there was a higher density of T cell subsets in the tumor core and regulatory T cells in all regions. A high density of FoxP3- CD4+ helper T cells in the tumor margin showed a trend toward better progression-free survival (PFS) (p=0.092) and significantly better overall survival (OS) (p=0.012). In multivariate analyses, a high density of FoxP3- CD4+ helper T cells in the tumor margin was independently associated with favorable PFS and OS. ConclusionThe tumor margin is the major site for the active infiltration of T cell subsets with higher levels of LAG3 and TIM3 expression in BTC. The density of tumor margin-infiltrating FoxP3- CD4+ helper T cells may be associated with clinical outcomes in BTC patients treated with gemcitabine plus cisplatin.
Purpose The clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine plus cisplatin were investigated. Materials and Methods A total of 52 BTC patients treated with palliative gemcitabine plus cisplatin were included. Multiplexed immunohistochemistry was performed on tumor tissues, and immune infiltrates were separately analyzed for the stroma, tumor margin, and tumor core. Results The density of CD8+ T cells, FoxP3– CD4+ helper T cells, and FoxP3+ CD4+ regulatory T cells was significantly higher in the tumor margin than in the stroma and tumor core. The density of LAG3– or TIM3-expressing CD8+ T cell and FoxP3– CD4+ helper T cell infiltrates was also higher in the tumor margin. In extrahepatic cholangiocarcinoma, there was a higher density of T cell subsets in the tumor core and regulatory T cells in all regions. A high density of FoxP3– CD4+ helper T cells in the tumor margin showed a trend toward better progression-free survival (PFS) (p=0.092) and significantly better overall survival (OS) (p=0.012). In multivariate analyses, a high density of FoxP3– CD4+ helper T cells in the tumor margin was independently associated with favorable PFS and OS. Conclusion The tumor margin is the major site for the active infiltration of T cell subsets with higher levels of LAG3 and TIM3 expression in BTC. The density of tumor margin-infiltrating FoxP3– CD4+ helper T cells may be associated with clinical outcomes in BTC patients treated with gemcitabine plus cisplatin. KCI Citation Count: 0
Author Kim, Jwa Hoon
Ryoo, Baek-Yeol
Kim, Ki-Hun
Kim, Hyung-Don
Song, Ki Byung
Kim, Danbee
Lee, Sunmin
Kim, Kyu-pyo
Hwang, Dae Wook
Jeong, Jae Ho
Song, Gi‐Won
Kim, Sang-Yeob
Lee, Jae Hoon
Jung, Dong‐Hwan
Yoo, Changhoon
Hong, Seung-Mo
Ryu, Yeon-Mi
Shin, Jaehoon
Author_xml – sequence: 1
  givenname: Hyung-Don
  surname: Kim
  fullname: Kim, Hyung-Don
– sequence: 2
  givenname: Jwa Hoon
  surname: Kim
  fullname: Kim, Jwa Hoon
– sequence: 3
  givenname: Yeon-Mi
  surname: Ryu
  fullname: Ryu, Yeon-Mi
– sequence: 4
  givenname: Danbee
  surname: Kim
  fullname: Kim, Danbee
– sequence: 5
  givenname: Sunmin
  surname: Lee
  fullname: Lee, Sunmin
– sequence: 6
  givenname: Jaehoon
  surname: Shin
  fullname: Shin, Jaehoon
– sequence: 7
  givenname: Seung-Mo
  surname: Hong
  fullname: Hong, Seung-Mo
– sequence: 8
  givenname: Ki-Hun
  surname: Kim
  fullname: Kim, Ki-Hun
– sequence: 9
  givenname: Dong‐Hwan
  surname: Jung
  fullname: Jung, Dong‐Hwan
– sequence: 10
  givenname: Gi‐Won
  surname: Song
  fullname: Song, Gi‐Won
– sequence: 11
  givenname: Dae Wook
  surname: Hwang
  fullname: Hwang, Dae Wook
– sequence: 12
  givenname: Jae Hoon
  surname: Lee
  fullname: Lee, Jae Hoon
– sequence: 13
  givenname: Ki Byung
  surname: Song
  fullname: Song, Ki Byung
– sequence: 14
  givenname: Baek-Yeol
  surname: Ryoo
  fullname: Ryoo, Baek-Yeol
– sequence: 15
  givenname: Jae Ho
  surname: Jeong
  fullname: Jeong, Jae Ho
– sequence: 16
  givenname: Kyu-pyo
  surname: Kim
  fullname: Kim, Kyu-pyo
– sequence: 17
  givenname: Sang-Yeob
  surname: Kim
  fullname: Kim, Sang-Yeob
– sequence: 18
  givenname: Changhoon
  surname: Yoo
  fullname: Yoo, Changhoon
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32878426$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002676768$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNptkU1v1DAQhi1URLeFG2fkI6hk8Uccx5dKJaWwUiUqCGfLsZ3FNGsvtoPKv8e7WypAnEaaeeadj_cEHPngLQDPMVrWuKZvdMxLgghaclQ_AguCEKsEYc0RWGAm2ooI0R6Dk5S-IdTUlOMn4JiSlrc1aRYgft6q7NQEL13K0Q1zdsFD5Q28iWHtQ8pOw9VmOzmtdqUEwwj7eRNitfKjm3Isab-GV-Huhlawu6zPYA87O00JOg_fusmp-BP2UekMO-W1jU_B41FNyT67j6fgy9W7vvtQXX98v-ouritd4zZXTBFKmeEW1YKIsUGMD4pTS6mg2tSEYCOM5YYZ1mKDWszaYWCNHSkWnA-GnoJXB10fR3mrnQzK7eM6yNsoLz71KykaTkTTFvb8wG7nYWONtr4cNsltdJuy_r7z74p3X4vOD8lbTBCmReDlvUAM32ebsty4pMsblLdhTpLUVAheDtmhL_6c9TDktykFeH0AdAwpRTs-IBjJneeyeC53nsviecHJP7h2eW9W2dRN_2_6Bb9qr10
CitedBy_id crossref_primary_10_37349_etat_2023_00199
crossref_primary_10_3390_ph17121606
crossref_primary_10_1016_j_esmoop_2024_103969
crossref_primary_10_1158_1078_0432_CCR_24_1265
crossref_primary_10_3389_fmed_2022_857140
crossref_primary_10_3389_fonc_2022_969569
crossref_primary_10_1038_s41598_022_05694_x
crossref_primary_10_1186_s13045_021_01103_4
crossref_primary_10_2147_CMAR_S474348
crossref_primary_10_3389_fimmu_2024_1482291
crossref_primary_10_1186_s12943_024_02047_2
crossref_primary_10_1186_s13046_022_02340_2
crossref_primary_10_3390_nu16234134
crossref_primary_10_3892_ijo_2023_5585
crossref_primary_10_3389_fimmu_2025_1453344
crossref_primary_10_1016_j_biopha_2024_117080
Cites_doi 10.1016/S1470-2045(20)30109-1
10.1186/s40425-019-0797-4
10.1053/j.gastro.2018.08.030
10.1002/ijc.33013
10.1002/hep.30881
10.1016/j.cell.2020.05.017
10.1038/s41571-019-0175-7
10.1016/S2468-1253(19)30086-X
10.1038/labinvest.2014.155
10.1136/jitc-2020-000564
10.1038/s41577-018-0044-0
10.1038/s41577-020-0306-5
10.1038/nature13954
10.1056/NEJMoa0908721
10.1016/j.ejca.2019.07.022
10.1038/bjc.2013.610
10.1016/j.immuni.2018.03.023
10.1007/s00280-017-3353-2
10.4143/crt.2019.493
10.1038/bjc.2017.401
10.1016/j.humpath.2004.03.016
10.7554/eLife.36967
10.1016/j.humpath.2015.05.016
10.1016/S1470-2045(20)30157-1
10.1038/s41598-019-42986-1
10.1155/2012/890178
10.3390/cancers11030283
10.1007/s00262-012-1307-4
10.1158/1078-0432.CCR-11-3185
10.1101/cshperspect.a026583
ContentType Journal Article
Copyright Copyright © 2021 by the Korean Cancer Association 2021
Copyright_xml – notice: Copyright © 2021 by the Korean Cancer Association 2021
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ACYCR
DOI 10.4143/crt.2020.704
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
CrossRef

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2005-9256
EndPage 171
ExternalDocumentID oai_kci_go_kr_ARTI_9672968
PMC7812013
32878426
10_4143_crt_2020_704
Genre Journal Article
GrantInformation_xml – fundername: Asan Institute for Life Sciences, Asan Medical Center
  grantid: 2017IL0752
GroupedDBID ---
29B
5-W
53G
8JR
9ZL
AAYXX
ABDBF
ACUHS
ACYCR
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
E3Z
EBD
EF.
F5P
HYE
OK1
RPM
TR2
C1A
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c418t-5a2335d7e04929f6057ba73e3393cd4221d9de7d5d581d08158bb56ef31977bd3
ISSN 1598-2998
2005-9256
IngestDate Sun Mar 09 07:53:15 EDT 2025
Thu Aug 21 14:09:59 EDT 2025
Thu Jul 10 22:11:35 EDT 2025
Mon Jul 21 05:46:52 EDT 2025
Tue Jul 01 03:18:50 EDT 2025
Thu Apr 24 23:10:44 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords CD4+ helper T cells
Biliary tract neoplasms
Tumor margin
Multiplexed immunohistochemistry
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c418t-5a2335d7e04929f6057ba73e3393cd4221d9de7d5d581d08158bb56ef31977bd3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Hyung-Don Kim and Jwa Hoon Kim contributed equally to this work.
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC7812013
PMID 32878426
PQID 2439979293
PQPubID 23479
PageCount 10
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_9672968
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7812013
proquest_miscellaneous_2439979293
pubmed_primary_32878426
crossref_primary_10_4143_crt_2020_704
crossref_citationtrail_10_4143_crt_2020_704
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-01-01
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – month: 01
  year: 2021
  text: 2021-01-01
  day: 01
PublicationDecade 2020
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Cancer research and treatment
PublicationTitleAlternate Cancer Res Treat
PublicationYear 2021
Publisher Korean Cancer Association
대한암학회
Publisher_xml – name: Korean Cancer Association
– name: 대한암학회
References ref13
ref12
ref15
ref14
ref30
ref11
ref10
ref2
ref1
ref17
ref16
ref19
ref18
ref24
ref23
ref26
ref25
ref20
ref22
ref21
ref28
ref27
ref29
ref8
ref7
ref9
ref4
ref3
ref6
ref5
References_xml – ident: ref4
  doi: 10.1016/S1470-2045(20)30109-1
– ident: ref14
  doi: 10.1186/s40425-019-0797-4
– ident: ref23
  doi: 10.1053/j.gastro.2018.08.030
– ident: ref7
  doi: 10.1002/ijc.33013
– ident: ref24
  doi: 10.1002/hep.30881
– ident: ref25
  doi: 10.1016/j.cell.2020.05.017
– ident: ref11
  doi: 10.1038/s41571-019-0175-7
– ident: ref6
  doi: 10.1016/S2468-1253(19)30086-X
– ident: ref18
  doi: 10.1038/labinvest.2014.155
– ident: ref5
  doi: 10.1136/jitc-2020-000564
– ident: ref10
  doi: 10.1038/s41577-018-0044-0
– ident: ref9
  doi: 10.1038/s41577-020-0306-5
– ident: ref15
  doi: 10.1038/nature13954
– ident: ref1
  doi: 10.1056/NEJMoa0908721
– ident: ref2
  doi: 10.1016/j.ejca.2019.07.022
– ident: ref13
  doi: 10.1038/bjc.2013.610
– ident: ref22
  doi: 10.1016/j.immuni.2018.03.023
– ident: ref20
  doi: 10.1007/s00280-017-3353-2
– ident: ref8
  doi: 10.4143/crt.2019.493
– ident: ref12
  doi: 10.1038/bjc.2017.401
– ident: ref26
  doi: 10.1016/j.humpath.2004.03.016
– ident: ref19
  doi: 10.7554/eLife.36967
– ident: ref21
  doi: 10.1016/j.humpath.2015.05.016
– ident: ref3
  doi: 10.1016/S1470-2045(20)30157-1
– ident: ref29
  doi: 10.1038/s41598-019-42986-1
– ident: ref28
  doi: 10.1155/2012/890178
– ident: ref30
  doi: 10.3390/cancers11030283
– ident: ref27
  doi: 10.1007/s00262-012-1307-4
– ident: ref16
  doi: 10.1158/1078-0432.CCR-11-3185
– ident: ref17
  doi: 10.1101/cshperspect.a026583
SSID ssj0064371
Score 2.3088803
Snippet PurposeThe clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with...
The clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine...
Purpose The clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 162
SubjectTerms Biliary Tract Neoplasms - genetics
Biliary Tract Neoplasms - pathology
CD4-Positive T-Lymphocytes - metabolism
Female
Forkhead Transcription Factors - metabolism
Humans
Lymphocytes, Tumor-Infiltrating - immunology
Male
Original
Prognosis
의학일반
Title Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/32878426
https://www.proquest.com/docview/2439979293
https://pubmed.ncbi.nlm.nih.gov/PMC7812013
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002676768
Volume 53
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Cancer Research and Treatment, 2021, 53(1), , pp.162-171
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db5swFLXSVqr6Mu172Ze8aX1CdME2GB6bZFUyqdM0UalvFmDToaZQ0WRT9-t3bQMhWStteyGRMVjknFzfg--9RuhDkPIsZXLkssxPQaAw5qahz1yfjzIZwjUyNwGyX4LZGft87p8PBj96UUurZXqU_bozr-R_UIU2wFVnyf4Dst1NoQG-A75wBITh-FcY6_2EC2O3brqNq9rwfx1Ap4uxzvsh4-AZxqurqnbnZV4sTMXc8sKBGegrdZ3JlB2SsRM7E7VYmDDZcbEodFRdrFOpnIkmSN33Zm2L0xQMsjlyXeT6enXfUG52C2bFnfZX_W2C9s_EmVXr5m-3KzMtqKp0T4utzsDRVKn-mwri9d5UKGPRTNnTiNhK4q35tbWCN2hmbalnzfS2jWfg4QEwWa0jYcnoiNvti3twX18ZvCmIwZCRrULbdupuTu2gPcK5Xt7fOx5PxyftHK5XMz2bJqGH-9gf7ADtt5dv-DI7ZZ3fJVO2o2177kv8ED1odAc-tiR6hAaqfIz2T5vIiieobriE-1zCAChecwn3uYSrHP_JJWy5hIFLDo6xYRIuStwwCRsmYcubp-js5FM8mbnNfhxuxrxw6foJodSXXIGqJFEOQpinCaeK0ohmkhHiyUgqLn3pgwoCX9MP09QPVA5mnvNU0mdot6xK9QJhj4ajSCW6GqVkUrGIslDRMIj8JAuDhA2R0_6yImuK1es9UxYCRKuGRAAkQkMiAJIhOux6X9siLff0ew8gicusELqquv68qMRlLUA7zkUUgNAMwiF612IowNTq9bOkVNXqRhCt3Tk8Oh2i5xbTbriWEkPEN9DuOugBN8-UxXdTzp2Djw1C7OW993yFDtZ_p9dod1mv1BtwhZfp24a3vwFecLRI
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Spatial+Distribution+and+Prognostic+Implications+of+Tumor-Infiltrating+FoxP3-+CD4%2B+T+Cells+in+Biliary+Tract+Cancer&rft.jtitle=Cancer+research+and+treatment&rft.au=Kim%2C+Hyung-Don&rft.au=Kim%2C+Jwa+Hoon&rft.au=Ryu%2C+Yeon-Mi&rft.au=Kim%2C+Danbee&rft.date=2021-01-01&rft.eissn=2005-9256&rft.volume=53&rft.issue=1&rft.spage=162&rft_id=info:doi/10.4143%2Fcrt.2020.704&rft_id=info%3Apmid%2F32878426&rft.externalDocID=32878426
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1598-2998&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1598-2998&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1598-2998&client=summon